Abstract:Background: Triple-negative breast cancer (TNBC) is a highly heterogeneous group of cancers with no effective therapeutic targets hitherto. Thus molecular subtyping is necessary to better identify molecular-based therapies. While some classifiers have been established, no one has integrated the expression profiles of long-noncoding RNAs (lncRNAs) into such subtyping criterions. Considering the emerging important role of lncRNAs in gene regulation and other cellular processes, a novel classification integrating the transcriptome profiles of both messenger RNA (mRNA) and lncRNA would help us better understand the heterogeneity of TNBC and treat patients accordingly. Methods: Using human transcriptome microarray, we retrieved the transcriptome profiles of 165 consecutive TNBC samples. We used k-means clustering to classify the samples based on the most differentially expressed genes (standard deviationu003e0.65). Empirical cumulative distribution function was analyzed to determine the optimal number of subtypes. Then the new classifier was compared with the Lehmann/Pietenpol system, and survival analyses were performed to compare the recurrence-free survival (RFS) in different subtypes. Gene Ontology (GO) and pathway analyses were applied to determine the main function of the subtype-specific genes and pathways. We conducted co-expression network analysis to identify interactions between lncRNAs and mRNAs, and to predict possible functions of subtype specific lncRNAs. Results: All 165 TNBC tumors were classified into four distinct clusters, each displaying unique GOs and pathways. These include an immunomodulatory (IM) subtype, a luminal androgen receptor (LAR) subtype, a mesenchymal-like (MES) subtype and a basal-like and immune suppressed (BLIS) subtype, accounting for 17.0%, 17.6%, 33.3%, and 32.2% of the patients, respectively. The IM subtype had unique GOs and pathways involving immune cell process. The LAR subtype was highly enriched in hormonally regulated pathways. Enriched pathways in the MES subtype included ECM-receptor interaction, focal adhesion, and processes linked to growth factor signaling pathways. The BLIS subtype was characterized by downregulation of immune response gene and activation of cell cycle and DNA repair, and patients in this subtype experienced worse RFS compared to other subtypes (log-rank test,P=0.045), which was in concordance with the highly proliferative and immune-suppressed nature of these tumors. When analyzing the distribution of the Lehmann/Pietenpol subtypes in our classification system, we found that the two classification systems were significantly correlated (P=0.039). However, our novel classification was more concise and significantly connected with survival outcome. Subtype-specific lncRNAs were identified and their possible functions were predicted using co-expression network analysis. Conclusions: We developed a novel TNBC classification system integrating the expression profiles of both mRNAs and lncRNAs, and determined subtype-specific lncRNAs that are potential biomarkers and targets of TNBC. If further validated in larger population, our novel classification system could facilitate patient counseling and individualize treatment of TNBC. Citation Format: Liu Y-R, Jiang Y-Z, Xu X-E, Zuo W-J, Yu K-D, Jin X, Hu X, Wu J, Liu G-Y, Di G-H, Shao Z-M. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific lncRNAs of triple-negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-04-04.

Attempt Towards A Novel Classification of Triple-Negative Breast Cancer Using Immunohistochemical Markers

Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping

Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers

Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance

Subclassifying triple-negative breast cancers and its potential clinical utility

Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer

Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer

Comprehensive Transcriptome Analysis Identifies Novel Molecular Subtypes And Subtype-Specific Incrnas Of Triple-Negative Breast Cancer

Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy

Inflammatory Response-Based Subtyping and Potential Therapeutic Strategies for Triple-Negative Breast Cancer

Histo- and Clinico-Pathological Analysis of a Large Series of Triple-Negative Breast Cancer in a Single Center in China: Evidences on Necessity of Histological Subtyping and Grading

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response

Triple-negative breast cancer molecular subtyping and treatment progress

Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies

Clinicopathologic Analysis of Basal-Like Breast Carcinoma and Triple Negative Breast Carcinoma

Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern

Identification of Immune-Related Risk Characteristics and Prognostic Value of Immunophenotyping in TNBC

Single-cell Atlas Reveals a Distinct Immune Profile Fostered by T Cell-B Cell Crosstalk in Triple Negative Breast Cancer

Retyping of triple‐negative breast cancer based on clustering method

Gene Expression Profiling for Diagnosis of Triple-Negative Breast Cancer: A Multicenter, Retrospective Cohort Study